Proteostasis Therapeutics Inc. [NASDAQ: PTI] loss -6.38% on the last trading session, reaching $1.32 price per share at the time. The company report on August 6, 2020 that Proteostasis Therapeutics Reports Second Quarter 2020 Financial Results.
Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the second quarter ended June 30, 2020.
“The COVID-19 pandemic has highlighted the unmet needs of the CF community and reaffirmed our commitment to providing more treatment choices for people living with CF,” said Meenu Chhabra, President and Chief Executive Officer of Proteostasis Therapeutics. “Our team continues to work tirelessly to advance our mission and we anticipate announcing data from the ex vivo portion of the CHOICES development program in the fourth quarter of 2020, and plan to move into the clinical portion by year-end.”.
Proteostasis Therapeutics Inc. represents 56.72 million in outstanding shares, while the company has a total market value of $74.87 million with the latest information. PTI stock price has been found in the range of $1.31 to $1.4288.
If compared to the average trading volume of 1.16M shares, PTI reached a trading volume of 1277752 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Proteostasis Therapeutics Inc. [PTI]:
RBC Capital Mkts have made an estimate for Proteostasis Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on October 18, 2018. While these analysts kept the previous recommendation, Robert W. Baird raised their target price from $13 to $25. The new note on the price target was released on December 12, 2017, representing the official price target for Proteostasis Therapeutics Inc. stock.
The Average True Range (ATR) for Proteostasis Therapeutics Inc. is set at 0.12 The Price to Book ratio for the last quarter was 1.53, with the Price to Cash per share for the same quarter was set at 0.86.
Trading performance analysis for PTI stock
Proteostasis Therapeutics Inc. [PTI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.00. With this latest performance, PTI shares gained by 2.33% in over the last four-week period, additionally sinking by -19.51% over the last 6 months – not to mention a rise of 92.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PTI stock in for the last two-week period is set at 42.96, with the RSI for the last a single of trading hit 39.55, and the three-weeks RSI is set at 44.71 for Proteostasis Therapeutics Inc. [PTI]. The present Moving Average for the last 50 days of trading for this stock 1.4344, while it was recorded at 1.4460 for the last single week of trading, and 1.6197 for the last 200 days.
Proteostasis Therapeutics Inc. [PTI]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Proteostasis Therapeutics Inc. [PTI] shares currently have an operating margin of -1223.08. Proteostasis Therapeutics Inc.’s Net Margin is presently recorded at -1182.50.
Return on Total Capital for PTI is now -64.40, given the latest momentum, and Return on Invested Capital for the company is -62.64. Return on Equity for this stock declined to -66.91, with Return on Assets sitting at -53.54. When it comes to the capital structure of this company, Proteostasis Therapeutics Inc. [PTI] has a Total Debt to Total Equity ratio set at 21.15. Additionally, PTI Total Debt to Total Capital is recorded at 17.46, with Total Debt to Total Assets ending up at 15.58. Long-Term Debt to Equity for the company is recorded at 19.31, with the Long-Term Debt to Total Capital now at 15.94.
Reflecting on the efficiency of the workforce at the company, Proteostasis Therapeutics Inc. [PTI] managed to generate an average of -$1,343,750 per employee.Proteostasis Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.
Proteostasis Therapeutics Inc. [PTI]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Proteostasis Therapeutics Inc. posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 37.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PTI.
An analysis of insider ownership at Proteostasis Therapeutics Inc. [PTI]
There are presently around $15 million, or 22.40% of PTI stock, in the hands of institutional investors. The top three institutional holders of PTI stocks are: SPHERA FUNDS MANAGEMENT LTD. with ownership of 2,536,600, which is approximately 0% of the company’s market cap and around 17.86% of the total institutional ownership; VANGUARD GROUP INC, holding 1,827,842 shares of the stock with an approximate value of $2.41 million in PTI stocks shares; and BLACKROCK INC., currently with $1.4 million in PTI stock with ownership of nearly -0.255% of the company’s market capitalization.
Positions in Proteostasis Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 20 institutional holders increased their position in Proteostasis Therapeutics Inc. [NASDAQ:PTI] by around 802,721 shares. Additionally, 23 investors decreased positions by around 1,548,548 shares, while 17 investors held positions by with 8,726,708 shares. The mentioned changes placed institutional holdings at 11,077,977 shares, according to the latest SEC report filing. PTI stock had 7 new institutional investments in for a total of 275,762 shares, while 12 institutional investors sold positions of 1,045,554 shares during the same period.